About pcm

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

PCM Chinese Edition more

早期三阴性乳腺癌免疫检查点抑制剂回顾

三阴性乳腺癌(triple negative breast... More >>

人类肿瘤中BRAF改变的叙述性综述:诊断和预测意义

B-Raf原癌基因,丝氨酸/苏氨酸激酶( BRAF... More >>

营养影响疾病的潜在分子机制

人体约有50至70万亿个细胞,每个细胞都在高度复杂的生物系统网络中发挥... More >>
Case Report 
RET-mutated non-small cell lung cancer treated with pralsetinib: a case series
Alessandro Galletti, Marco Russano, Fabrizio Citarella, Giuseppina Di Fazio, Valentina Santo, Leonardo Brunetti, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine  
2022;
5:
20  
Case Report 
Ineffective target therapy in non-small cell lung cancer harboring BRAF G466R mutation: a case report and biological rationale
Fabrizio Citarella, Marco Russano, Giuseppe Perrone, Giuseppina-Rita Di Fazio, Raffaele Giusti, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine  
2022;
5:
19  
Case Report 
KRAS G12V mutation as an acquired resistance mechanism after treatment with dabrafenib and trametinib in non-small cell lung cancer harbouring the BRAF V600E mutation: a case report
Hajime Oi, Kiyotaka Yoh, Shingo Matsumoto, Hiroki Izumi, Yuji Shibata, Tetsuya Sakai, Kaname Nosaki, Yoshitaka Zenke, Koichi Goto
Precision Cancer Medicine  
2022;
5:
18  
Review Article 
Current evidence of BRCA mutations in genitourinary and gynecologic tumors: a scoping review
Alain Chebly, Tony Yammine, Elie Rassy, Stergios Boussios, Michele Moschetta, Chantal Farra
Precision Cancer Medicine  
2022;
5:
17  
Review Article 
The role of digital and integrative pathology for the detection of translocations: a narrative review
Carlo Beretta, Stefano Ceola, Fabio Pagni, Vincenzo L’Imperio
Precision Cancer Medicine  
2022;
5:
16  
Review Article 
Drug-related toxicity in breast cancer patients: a new path towards tailored treatment?—a narrative review
Eleonora Lai, Mara Persano, Marco Dubois, Dario Spanu, Clelia Donisi, Marta Pozzari, Giulia Deias, Giorgio Saba, Marco Migliari, Nicole Liscia, Mariele Dessì, Mario Scartozzi, Francesco Atzori
Precision Cancer Medicine  
2022;
5:
15  
Review Article 
The past, present, and future of non-metastatic castration-resistant prostate cancer (nmCRPC): a narrative review
Natalia Vidal, Juan Gómez Rivas, Laura Fernández, Jesús Moreno, Javier Puente
Precision Cancer Medicine  
2022;
5:
14  
Review Article 
A narrative review of the management of BRAF non-V600E mutated metastatic non-small cell lung cancer
Inas Abuali, Chung-Shien Lee, Nagashree Seetharamu
Precision Cancer Medicine  
2022;
5:
13  
Original Article 
Prospective and single-blinded evaluation of the multi-cancer Carcimun-test
Andreas Salat, Wieland Voigt, Berthold von und zu Zwerger
Precision Cancer Medicine  
2022;
5:
12  
Editorial 
From icing to slicing the cake: the new hope of precision medicine for lung cancer
Giuseppe L. Banna, Alfredo Addeo
Precision Cancer Medicine  
2022;
5:
11  
Case Report 
Efficacy of pembrolizumab in lung adenocarcinoma harboring non-V600E BRAF mutation: a case report
Giuseppina-Rita Di Fazio, Fabrizio Citarella, Emanuela Dell’Aquila, Marco Russano, Alessandro Galletti, Valentina Santo, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine  
2022;
5:
10  
Case Report 
Uncommon EGFR mutations: state-of-the-art and case reports
Francesca Simionato, Lorenzo Calvetti
Precision Cancer Medicine  
2022;
5:
9  
Case Report 
ALK non-small cell lung cancer sequence of treatment: a case report
Alonso García Miriam, Sánchez Gastaldo Amparo, Bernabé Caro Reyes, Benedetti Pedroza Johana Cristina, Carrasco García Irene
Precision Cancer Medicine  
2022;
5:
8  
Case Report 
Primary lung secretory carcinoma: a case report
Huihua Li, Darya Buehler, Jefree J. Schulte
Precision Cancer Medicine  
2022;
5:
7  
Review Article 
New driver alterations in non-small cell lung cancer: a narrative review
Marco Filetti, Alessandro Rossi, Beatrice Taurelli Salimbeni, Marta Piras, Evelina Rogges, Arianna Di Napoli, Paolo Marchetti, Raffaele Giusti
Precision Cancer Medicine  
2022;
5:
5  
Review Article 
Mechanisms of resistance after crizotinib or second-generation ALK therapy in advanced non-small cell lung cancer
Jordi Remon, Laura Esteller, Lizza E. L. Hendriks
Precision Cancer Medicine  
2022;
5:
4  
Review Article 
Role of radiation therapy in triple negative breast cancer: current state and future directions—a narrative review
Fares Azoury, Shagun Misra, Aisling Barry, Joelle Helou
Precision Cancer Medicine  
2022;
5:
3  
Original Article 
Outcomes of head and neck angiosarcoma with different treatment modalities: a 20-year single institutional experience
Yen Sin Koh, Jason Yongsheng Chan, Wen Shen Looi, Mohamad Farid, N Gopalakrishna Iyer, Ci-An Gerald Tay, Kiattisa Sommat, Ru Xin Wong
Precision Cancer Medicine  
2022;
5:
2  
Editorial 
ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy
Ernest Nadal, Laura Mezquita, Jesús Corral
Precision Cancer Medicine  
2022;
5:
1  

Review Article

Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review
Francesca Parisi, Giovanni Rossi, Federica Biello, Marco Tagliamento, Giulia Barletta, Lodovica Zullo, Eugenia Cella, Gianluca Sacco, Chiara Dellepiane, Elisa Bennicelli, Diletta Favero, Angela Alama, Simona Coco, Silvia Marconi, Linda Zinoli, Enrica Teresa Tanda, Paolo Pronzato, Erika Rijavec, Carlo Genova

Editorial Commentary


Editorial

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?
Diogo A. Bastos, Emmanuel S. Antonarakis

Case Report: Precision Oncology Tumor Board

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J. Piper-Vallillo, Hollis Viray, Adeel M. Khan, Deepa Rangachari, Daniel B. Costa